Skip to content

    Poly Medicure

    POLYMEDGood
    Healthcare·6 Feb 2026
    Management Summary

    Poly Medicure is undergoing a strategic transition from low-technology products to high-complexity, high-growth segments like cardiology and orthopedics. Despite headwinds in the export market and aggressive Chinese dumping, the company achieved double-digit consolidated revenue growth, largely aided by recent European acquisitions. Management is focused on the domestic private market and high-end R&D products to drive future margins and market share.

    Highlights

    8

    • Consolidated revenue reached ₹494 crores, representing a 16.4% YoY and 11.2% QoQ growth.

    • Gross margin expanded to 68.4%, an increase of 300 bps compared to the same quarter last year.

    • Operating EBITDA for Q3 stood at ₹119 crores (24.2% margin), excluding acquisition-related costs.

    • Domestic private market business grew by 22.5%, while government business saw a deliberate degrowth of 18%.

    • Acquisitions of PendraCare and Citieffe Group added approximately ₹48-49 crores to the top line in Q3.

    • Renal business revenue grew 15.1% YoY to ₹45 crores, with over 300 dialysis machines sold year-to-date.

    • Management guided for 20% overall revenue growth in FY27, driven by 25% domestic growth.

    • Liquidity remains strong with ₹840 crores in cash to support organic and inorganic growth strategies.

    Concerns

    1

    • Aggressive Chinese Dumping

    Key financials

    Metrics

    5

    Periods

    2

    Headline

    4
    • Revenue
      ₹494 Cr
      YoY+16.4%QoQ+11.2%
    • Operating EBITDA Margin
      24.2%
    • PAT
      ₹71 Cr
    • Gross Margin
      68.4%

    9M

    1
    • Consolidated Revenue
      ₹1,341 Cr
      YoY+9.1%

    Segment breakdown

    Revenue GrowthRevenue
    Domestic Business16.2%—
    International Business16.6%₹342 Cr
    Renal Business15.1%₹45 Cr
    Heatmap· 2 shared metrics

    Guidance & targets

    7
    CategoryTargetPriority
    Revenue
    H2 Consolidated Revenue Growth vs H1
    20%
    		High
    Revenue
    Total Business Revenue Growth
    20%+
    		Medium
    Revenue
    Domestic Business Growth
    25%
    		Medium
    Revenue
    Export Business Growth
    12% to 15%
    		Medium
    Volume
    Dialysis Machine Sales
    450
    		Medium
    Market Share
    Dialysis Market Share
    15% to 17%
    		Medium
    Capacity
    New Plants Operational
    3
    		High

    Risks & concerns

    4
    RiskSeverity

    Aggressive Chinese Dumping

    Chinese suppliers are dumping products at low prices in global markets (excluding the US) and using FTA countries to enter India at 0% duty. — Management acknowledged

    high

    Regulatory Transition (EU MDR)

    Transition from MDD to MDR in Europe caused delays and forced the company to drop some products temporarily while awaiting new approvals. — Management acknowledged

    medium

    Government Business Payment Delays

    Delays in state government payments and lower pricing have led the company to deliberately reduce its government business exposure. — Management acknowledged

    medium

    Areas of Evasion(1)

    • Specific revenue mix for FY27 (cardio vs renal vs infusion) was not provided as the business plan is still being finalized.

    Q&A highlights

    3

    “Yes, that is correct... we face certain headwinds on the export front, especially in the European markets. And I think that was the main reason for lower growth of stand-alone revenue.”

    Clarifies that the 16% consolidated growth was heavily inorganic, while the core standalone business faced significant export headwinds.

    asked by Suruchi Parmar

    2 min read5 chapters

    Detailed Narrative

    01

    Strategic Pivot to High-Complexity Medtech

    Poly Medicure is aggressively transitioning from low-tech consumables to high-complexity segments like cardiology, critical care, and orthopedics. The company recently received DCGI approval for next-generation products, including Intravenous Lithotripsy (IVL) and Drug Eluting Balloons (DEB), which are currently 90% import-dependent in India. These products carry high Average Selling Prices (ASP) in excess of ₹1,15,000, signaling a move up the value chain to create higher entry barriers.

    02

    Acquisition Integration and European Footprint

    The successful acquisitions of PendraCare and Citieffe Group have significantly expanded Polymed's European footprint, providing a 'Made in Europe' advantage and faster regulatory access. These entities added approximately ₹48-49 crores to the Q3 top line and are currently operating at 50-60% capacity. Management expects the full-year impact of these acquisitions to be visible in FY27, with synergies realized over the next few years as they leverage Indian manufacturing for cost competitiveness.

    03

    Domestic Market Dynamics and Private Sector Focus

    The company is deliberately shifting away from government business, which saw an 18% degrowth, toward the more stable and higher-margin private market. The private domestic business grew by 22.5% in Q3 and now constitutes 88% of domestic revenue. Polymed has added 80-90 new sales representatives in the last 9 months to deepen engagement with corporate hospitals, aiming for a 25% domestic growth rate in FY27.

    04

    Navigating Global Headwinds and Chinese Competition

    International business grew 16.6% YoY to ₹342 crores, but the organic standalone portion remained flattish due to aggressive Chinese dumping and freight crises. Management is countering this by shifting from a distributor-led model to a clinical-led model, deploying internal clinical teams to Europe to demonstrate product superiority. They have won new contracts with the NHS in the UK and in Germany, which are expected to drive a recovery in export growth to 12-15% in FY27.

    05

    Manufacturing Expansion and R&D Investment

    Polymed invested ₹234 crores in capex during the first 9 months of FY26 to set up new factories in Mitrol, Haridwar, and Jewar. These facilities are expected to be fully operational within 18-24 months. Additionally, the company is investing heavily in R&D and clinical teams, hiring over 100 skilled professionals this year to support high-end product development and international clinical training through its PACE Academy.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.